National Academy of Medicine

Implementation of Pharmacogenomics: Evidence Needs

By Mary V. Relling, David L. Veenstra
February 26, 2015 | Commentary

The evidentiary needs for genomic technologies are a significant barrier to the translation of genomic testing into clinical use. However, in many instances there is sufficient evidence to justify the use of genetic testing to information choice or dosage of medications. This discussion paper, the last of seven individually authored commentaries that explores the evidence needed to support the use of genome sequencing in the clinic, examines the policy issues and evidence needs for implementing pharmacogenomics testing.



Suggested Citation

Relling, M. W. and D. L. Veenstra. 2015. Implementation of Pharmacogenomics: Evidence Needs. NAM Perspectives. Commentary, National Academy of Medicine, Washington, DC. doi: 10.31478/201502j


Disclaimer: The views expressed in this paper are those of the authors and not necessarily of the authors’ organizations, the National Academy of Medicine (NAM), or the National Academies of Sciences, Engineering, and Medicine (the National Academies). The paper is intended to help inform and stimulate discussion. It is not a report of the NAM or the National Academies. Copyright by the National Academy of Sciences. All rights reserved.